The recently approved factor B inhibitor iptacopan (as monotherapy) and factor D inhibitor danicopan (as add-on therapy) also improve outcomes in C5 inhibitor–experienced patients with PNH and residual anemia; both treatments inhibit the alternative pathway, one of the activation pathways of the proximal complement cascade [16,17]. This evidence concerns the gene C5 and anemia (phenotype).